Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, focused on breaking new ground in recovering hearts and saving lives. Because hundreds of people die each year waiting for heart transplants, Abiomed CEO, Chairman and President, Michael R. Minogue has focused the company’s efforts on developing ground-breaking “bridge to recovery” medical technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The company’s portfolio of heart recovery products and services offer healthcare professionals an array of choices across a broad clinical spectrum. Abiomed’s minimally invasive devices enable the heart to rest, heal and recover by improving blood flow and circulatory support. Through the use of Abiomed’s heart recovery products, patients can return home to live longer and fuller lives with their own native heart. Abiomed was founded more than two decades ago in 1981 and is the only company in the world with exclusive labeling on circulatory support and ventricular assist devices (VADs) for all potentially recoverable heart failure indications. As the global leader for products in the acute heart failure market, the Company ships more heart recovery pumps and VADs than any other company in the world. With a growing staff of over 300 employees, Abiomed is headquartered in Danvers, Mass., and additional offices in Aachen, Germany and Ireland. From the world’s first total replacement heart to a catheter-based device that provides circulatory support with rapid and simple insertion, Abiomed is dedicated to finding ways to treat heart failure so that patients and physicians have the most advanced, successful, and beneficial technology available to improve quality of life.
22 Cherry Hill Drive
News | Heart Failure| June 28, 2016
June 28, 2016 — A recent report published by Allied Market Research, titled, "Congestive Heart Failure (CHF) Treatmen
Technology | Ventricular Assist Devices (VAD)| April 11, 2016
Abiomed Inc. announced that it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for its...
News | Ventricular Assist Devices (VAD)| July 09, 2015
During an event with Massachusetts Gov. Charlie Baker in June, Abiomed announced a major expansion of its U.S....
News | Ventricular Assist Devices (VAD)| June 11, 2015
ECRI Institute recently reviewed published data on Abiomed's Impella RP (Right Percutaneous) transcatheter ventricular...
News | Ventricular Assist Devices (VAD)| June 09, 2015
University Hospitals Case Medical Center physicians in the Harrington Heart & Vascular Institute were the first in...
News | June 04, 2015
Beaumont Hospital, Royal Oak is one of the first centers in the United States to use a new minimally invasive heart...
Technology | March 25, 2015
The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) clearance for Abiomed’s Impella 2.5...
Feature | January 28, 2015
Abiomed Inc. said the Impella RP (Right Percutaneous) system has received U.S. Food and Drug Administration (FDA)...
Feature | March 18, 2014 | Dave Fornell
Percutaneous ventricular assist (pVAD) devices offer more hemodynamic support than the 40-year-old gold standard of ...
Feature | January 20, 2014 | Dave Fornell
The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 offers many new insights...